Relmada CMO buys 55,000 RLMD shares on open market

Relmada Therapeutics reported that its Chief Medical Officer-Urology, Raj S. Pruthi, MD, purchased 55,000 shares of the Company’s common stock in open market transactions on August 29, 2025.

Rhea-AI Filing Summary

Relmada Therapeutics reported that its Chief Medical Officer-Urology, Raj S. Pruthi, MD, purchased 55,000 shares of the Company’s common stock in open market transactions on August 29, 2025. This insider purchase reflects a direct acquisition of additional equity by a senior executive using the public market rather than through company grants or option exercises. The disclosure is provided under Regulation FD as furnished information, meaning it is not treated as filed under certain Exchange Act liability provisions or automatically incorporated into other securities law filings.

8-K Event Classification

Item 7.01 — Regulation FD Disclosure

1 item

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did RLMD disclose in this Form 8-K?

The Company disclosed that Raj S. Pruthi, MD, Chief Medical Officer-Urology of Relmada Therapeutics, purchased 55,000 shares of its common stock in open market transactions on August 29, 2025.

Who bought Relmada Therapeutics (RLMD) shares and how many?

Raj S. Pruthi, MD, the Company’s Chief Medical Officer-Urology, bought 55,000 shares of Relmada Therapeutics’ common stock in open market transactions.

What type of stock did the Relmada Therapeutics executive purchase?

The executive purchased common stock of Relmada Therapeutics, with a par value of $0.001 per share, in open market transactions.

Is the insider share purchase information considered filed with the SEC?

No. The Company states that the information under Item 7.01 is being furnished, not filed, and therefore is not subject to Section 18 liability and is not incorporated into other Securities Act or Exchange Act filings unless specifically referenced.

On which exchange is Relmada Therapeutics common stock listed and under what symbol?

Relmada Therapeutics’ common stock is listed on The NASDAQ Capital Market under the trading symbol RLMD.

Who signed the Form 8-K for Relmada Therapeutics?

The Form 8-K was signed on behalf of Relmada Therapeutics, Inc. by Sergio Traversa, the Company’s Chief Executive Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/02/2025 - 07:30 AM EDT Learn about SEC filing dates

false 0001553643 0001553643 2025-08-29 2025-08-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 29, 2025

RELMADA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Nevada		001-39082		45-5401931
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

2222 Ponce de Leon Blvd., Floor 3 Coral Gables, FL		33134
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (786) 629-1376

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of exchange on which registered
Common stock, $0.001 par value per share		RLMD		The NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On August 29, 2025, Raj S. Pruthi, MD, Chief Medical Officer-Urology of Relmada Therapeutics, Inc. (the “Company”), purchased in open market transactions 55,000 shares of the Company's common stock, $0.001 par value per share. 

In accordance with General Instruction B.2 of Form 8-K, the information in this Item 7.01 of this Current Report on Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: September 2, 2025	RELMADA THERAPEUTICS, INC.
	By:	/s/ Sergio Traversa
	Name:	Sergio Traversa
	Title:	Chief Executive Officer

2